Otsuka America Pharmaceutical, Inc. (OAPI) is a successful, innovative, fast-growing healthcare company that commercializes Otsuka-discovered and other product opportunities in North America. Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) is dedicated to developing and commercializing innovative healthcare products, on a global basis, that address unmet medical needs.
Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer, using its proprietary ribonuclease (RNase) technology platform.Ê It is committed to the development of a leading-edge oncology franchise of targeted therapies and differentiated, first-in-class cytotoxic agents.
CuraGen Corporation is a biopharmaceutical company dedicated to improving the lives of patients by developing novel pharmaceutical products that address unmet medical needs. CuraGen's deep understanding of the human genome has enabled us to gain greater insight into the molecular basis of disease. The Company's therapeutics are based on novel drug targets that are believed to play a role in proven mechanisms underlying disease. CuraGen has translated this understanding into a pipeline of protein, antibody, and small molecule drugs in the areas of oncology, inflammatory diseases, and diabetes. The Company's strategy remains focused on advancing its pipeline of promising therapeutics through clinical and preclinical development.
Genentech BioOncology Translating science into life
At Genentech BioOncology, we're fundamentally transforming the way cancer is treated, with the goal of moving cancer toward a more manageable disease. Our research efforts are conducted by scientists dedicated to improving patients' lives by defining the molecular basis of cancer and investigating multiple approaches to treating the disease. Our commitment to this goal has enabled us to make significant contributions to the understanding of cancer and to translate this understanding into targeted biologic-based therapies.
IDM Pharma, Inc. Immunotherapy designed to combat cancer while maintaining quality of life.
IDM is a biopharmaceutical company focused on the development of innovative products that activate the immune system to treat cancer. Our mission is to provide highly effective treatments that maintain quality of life. To date, more than 10,000 injections have been safely administered during the course of IDM clinical trials. We have demonstrated that our products have low toxicity and are well tolerated by patients.
Sanofi-aventis Every day, everywhere, we at sanofi-aventis are working for what really matters: health
Sanofi-aventis is one of the world leaders in the pharmaceutical industry, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines.
Have a comment or suggestion? Want to learn more? We want to hear from you! 888-380-6500